JZL184

JZL184 is a drug that acts as a selective inhibitor of the enzyme monoacylglycerol lipase (MAGL). It has been used in scientific research to explore the role of MAGL in degradation of the endocannabinoid 2-arachidonoylglycerol (2-AG), and its possible applications in the treatment of diseases such as neuroinflammation, neurodegenerative diseases, and cancer.

Pharmacology

JZL184 is a potent and selective inhibitor of MAGL, the primary enzyme responsible for degrading the endocannabinoid 2-AG. By inhibiting MAGL, JZL184 increases levels of 2-AG in the brain, leading to enhanced cannabinoid receptor activation. This can produce a range of effects, including analgesia, anti-inflammation, and neuroprotection.

Therapeutic Potential

Research has suggested that JZL184 may have therapeutic potential in a variety of conditions. These include neuroinflammatory and neurodegenerative diseases, where increased 2-AG signaling can reduce inflammation and protect neurons from damage. In addition, JZL184 has been shown to reduce the growth and spread of certain types of cancer, potentially through its effects on the endocannabinoid system.

Side Effects

Like other drugs that increase cannabinoid signaling, JZL184 can produce side effects such as sedation, hypothermia, and ataxia. However, these effects are generally mild and may be outweighed by the potential therapeutic benefits of the drug.

See Also

• Monoacylglycerol lipase
• 2-Arachidonoylglycerol
• Endocannabinoid system

JZL184 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia